Alcobra Ltd., traded as ADHD on the NASDAQ stock exchange, is a biopharmaceutical company that specializes in developing treatments for central nervous system (CNS) disorders. The company was founded in 2008 and is headquartered in Tel Aviv, Israel, with a research and development facility in Utah, United States.
Alcobra's lead product candidate is metadoxine extended-release (MDX), a drug that has completed Phase III clinical trials for the treatment of attention deficit hyperactivity disorder (ADHD) in adults. MDX is designed to improve executive function and behavioral inhibition in adults with ADHD, who often struggle with cognitive impairment and lack of impulse control.
In addition to MDX, Alcobra is also developing other CNS disorder treatments, including a treatment for Fragile X Syndrome and a drug that improves cognitive function in patients with schizophrenia.
Alcobra's research and development efforts are focused on developing innovative treatments that address unmet needs in the CNS disorder market. The company's team of scientists and researchers collaborate with academic institutions and other biopharmaceutical companies to identify new drug targets and develop new therapeutic approaches.
As of September 2021, Alcobra Ltd. had a market capitalization of approximately $29 million. The company operates with a small team of employees and relies on strategic partnerships and collaborations to advance its research and development efforts. However, in early 2021, the company announced that it had entered into a definitive merger agreement with Arcturus Therapeutics Holdings Inc., a clinical-stage messenger RNA medicines company, in a transaction valued at approximately $298 million.
|
